Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dr Hank Mansbach joins Medivation

This article was originally published in Scrip

Executive Summary

Dr Hank Mansbach has been named vice-president of medical affairs at Medivation (US). He will lead the company's medical affairs activities for Dimebon (latrepirdine), its Phase III candidate for the treatment of Alzheimer's and Huntington diseases, and MDV3100, which is in Phase III development for the treatment of advanced prostate cancer and has just been licensed to Astellas. Dr Mansbach is a neurologist with more than 10 years' drug development experience, having previously served as senior vice-president and head of global drug development at Valeant Pharmaceuticals.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts